Weight and mechanical performance optimization of blended composite wing panels using lamination parameters

In this paper, a lamination parameter-based approach to weight optimization of composite aircraft wing structures is addressed. It is a bi-level procedure where at the top level lamination parameters and numbers of plies of the pre-defined angles (0, 90, 45 and −45°) are used as design variables, the material volume is treated as an objective function to be minimized subject to the buckling, strength and ply percentage constraints. At the bottom level the optimum stacking sequence is obtained subject to the requirements on blending and preservation of mechanical properties. To ensure composite blending, a multi-stage optimization is performed by a permutation genetic algorithm aiming at matching the lamination parameters passed from the top level optimization as well as satisfying the layup rules. Two new additional criteria, the 90° ply angle jump index and the stack homogeneity index, are introduced to control the uniformity of the three ply angles (0, 90, 45 and −45) spread throughout the stack as well as improve the stack quality and mechanical performance by encouraging 45° angle change between neighbouring groups of plies. The results of the application of this approach are compared to published results to demonstrate the potential of the developed technique

A general global-local modelling framework for the deterministic optimisation of composite structures

This work deals with the multi-scale optimisation of composite structures by adopting a general global-local (GL) modelling strategy to assess the structure responses at different scales. The GL modelling approach is integrated into the multi-scale two-level optimisation strategy (MS2LOS) for composite structures. The resulting design strategy is, thus, called GL-MS2LOS and aims at proposing a very general formulation of the design problem, without introducing simplifying hypotheses on the laminate stack and by considering, as design variables, the full set of geometric and mechanical parameters defining the behaviour of the composite structure at each pertinent scale. By employing a GL modelling approach, most of the limitations of well-established design strategies, based on analytical or semi-empirical models, are overcome. The GL-MS2LOS makes use of the polar formalism to describe the anisotropy of the composite at the macroscopic scale (where it is modelled as an equivalent homogeneous anisotropic plate). In this work, deterministic algorithms are exploited during the solution search phase. The challenge, when dealing with such a design problem, is to develop a suitable formulation and dedicated operators, to link global and local models physical responses and their gradients. Closed-form expressions of structural responses gradients are rigorously derived by taking into account for the coupling effects when passing from global to local models. The effectiveness of the GL-MS2LOS is proven on a meaningful benchmark: the least-weight design of a cantilever wing subject to different design requirements. Constraints include maximum allowable displacements, maximum allowable strains, blending, manufacturability requirements and buckling factor.This work deals with the multi-scale optimisation of composite structures by adopting a general global-local (GL) modelling strategy to assess the structure responses at different scales. The GL modelling approach is integrated into the multi-scale two-level optimisation strategy (MS2LOS) for composite structures. The resulting design strategy is, thus, called GL-MS2LOS and aims at proposing a very general formulation of the design problem, without introducing simplifying hypotheses on the laminate stack and by considering, as design variables, the full set of geometric and mechanical parameters defining the behaviour of the composite structure at each pertinent scale. By employing a GL modelling approach, most of the limitations of well-established design strategies, based on analytical or semi-empirical models, are overcome. The GL-MS2LOS makes use of the polar formalism to describe the anisotropy of the composite at the macroscopic scale (where it is modelled as an equivalent homogeneous anisotropic plate). In this work, deterministic algorithms are exploited during the solution search phase. The challenge, when dealing with such a design problem, is to develop a suitable formulation and dedicated operators, to link global and local models physical responses and their gradients. Closed-form expressions of structural responses gradients are rigorously derived by taking into account for the coupling effects when passing from global to local models. The effectiveness of the GL-MS2LOS is proven on a meaningful benchmark: the least-weight design of a cantilever wing subject to different design requirements. Constraints include maximum allowable displacements, maximum allowable strains, blending, manufacturability requirements and buckling factor

A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit.

BACKGROUND: Community-acquired bacterial pneumonia (CABP) can lead to sepsis and is associated with high mortality rates in patients presenting with shock and/or respiratory failure and who require mechanical ventilation and admission to intensive care units, thus reflecting the limited effectiveness of current therapy. Preclinical studies support the efficacy of expanded allogeneic adipose-derived mesenchymal stem cells (eASCs) in the treatment of sepsis. In this study, we aim to test the safety, tolerability and efficacy of eASCs as adjunctive therapy in patients with severe CABP (sCABP). METHODS: In addition to standard of care according to local guidelines, we will administer eASCs (Cx611) or placebo intravenously as adjunctive therapy to patients with sCABP. Enrolment is planned for approximately 180 patients who will be randomised to treatment groups in a 1:1 ratio according to a pre-defined randomization list. An equal number of patients is planned for allocation to each group. Cx611 will be administered on Day 1 and on Day 3 at a dose of 160 million cells (2 million cells / mL, total volume 80 mL) through a 20-30 min (240 mL/hr) intravenous (IV) central line infusion after dilution with Ringer Lactate solution. Placebo (Ringer Lactate) will also be administered through a 20-30 min (240 mL/hr) IV central line infusion at the same quantity (total volume of 80 mL) and following the same schedule as the active treatment. The study was initiated in January 2017 and approved by competent authorities and ethics committees in Belgium, Spain, Lithuania, Italy, Norway and France; monitoring will be performed at regular intervals. Funding is from the European Union's Horizon 2020 Research and Innovation Program. DISCUSSION: SEPCELL is the first trial to assess the effects of eASCs in sCABP. The data generated will advance understanding of the mode of action of Cx611 and will provide evidence on the safety, tolerability and efficacy of Cx611 in patients with sCABP. These data will be critical for the design of future confirmatory clinical investigations and will assist in defining endpoints, key biomarkers of interest and sample size determination. TRIAL REGISTRATION: NCT03158727 , retrospectively registered on 9 May 2017